Andra AP fonden Decreases Position in AbbVie Inc. $ABBV

Andra AP fonden lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 268,811 shares of the company’s stock after selling 15,000 shares during the period. AbbVie comprises approximately 0.7% of Andra AP fonden’s holdings, making the stock its 23rd biggest position. Andra AP fonden’s holdings in AbbVie were worth $67,644,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. State Street Corp grew its stake in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. Premier Financial Group acquired a new position in AbbVie during the 2nd quarter worth $250,000. Security National Bank of Sioux City Iowa IA grew its stake in AbbVie by 13.3% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 16,964 shares of the company’s stock worth $4,269,000 after purchasing an additional 1,995 shares in the last quarter. Reynders McVeigh Capital Management LLC increased its holdings in AbbVie by 0.4% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 29,167 shares of the company’s stock worth $7,340,000 after purchasing an additional 115 shares during the period. Finally, Bullseye Investment Management LLC acquired a new stake in AbbVie in the second quarter valued at approximately $170,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

NYSE:ABBV traded up $1.03 during trading hours on Tuesday, reaching $265.51. 892,624 shares of the company were exchanged, compared to its average volume of 6,538,061. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The firm has a market cap of $469.10 billion, a price-to-earnings ratio of 75.07, a PEG ratio of 1.19 and a beta of 0.29. The stock has a 50 day simple moving average of $255.90 and a 200 day simple moving average of $232.37.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RINVOQ gains another European indication. The European Commission approved RINVOQ (upadacitinib) for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, one or more DMARDs. The approval expands RINVOQ’s commercial reach and adds to its 11 approved EU indications, reinforcing the drug as a key growth driver for AbbVie. AbbVie Announces European Commission Approval of RINVOQ
• Positive Sentiment: AbbVie expands its AI drug-discovery strategy. AbbVie entered a multiyear collaboration with Iambic to use the company’s AI platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The partnership could improve discovery efficiency and diversify AbbVie’s long-term pipeline, although any financial benefits are likely to take years to materialize. AbbVie and Iambic Announce Collaboration
• Positive Sentiment: Allergan Aesthetics launched AA Signature: SKIN360 in the U.S. The multimodal consultation program is intended to help providers address patients’ broader aesthetic goals and could support engagement across AbbVie’s aesthetics portfolio. The near-term earnings impact is not specified. Allergan Aesthetics Debuts AA Signature
• Neutral Sentiment: Recent commentary continues to highlight AbbVie’s dividend appeal and second-quarter results, which exceeded analyst expectations for both earnings and revenue. These reports support the stock’s defensive investment case, but largely reiterate previously reported information rather than provide a new catalyst. AbbVie vs. Pfizer

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ABBV shares. Citigroup boosted their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Cantor Fitzgerald restated an “overweight” rating on shares of AbbVie in a research report on Wednesday, September 16th. UBS Group boosted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Piper Sandler increased their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus target price of $276.64.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.